Ling V, Gerlach J, Kartner N
Breast Cancer Res Treat. 1984;4(2):89-94. doi: 10.1007/BF01806390.
Mutations resulting in a complex phenotype of cross-resistance and collateral-sensitivity are frequently observed in mammalian cell lines. A cell surface 170 000 dalton glycoprotein (P-glycoprotein) has been identified to be intimately associated with this multidrug resistance phenotype. We speculate that such mutations also occur in advanced cancers and play a major role in contributing to the non-response to combination chemotherapy. In this context, P-glycoprotein may be a useful molecular marker for diagnostic and therapeutic applications.
在哺乳动物细胞系中经常观察到导致交叉耐药和 collateral-敏感性复杂表型的突变。一种细胞表面170000道尔顿的糖蛋白(P-糖蛋白)已被确定与这种多药耐药表型密切相关。我们推测这种突变也发生在晚期癌症中,并在导致联合化疗无反应中起主要作用。在这种情况下,P-糖蛋白可能是一种用于诊断和治疗应用的有用分子标志物。